MedTrace Logo

Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy

NCT02976194 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-10-10

No results posted yet for this study

Summary

Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.

Conditions

  • Exudative Age-related Macular Degeneration
  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

ranibizumab

Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Ji Eun Lee, MD, PhD · Pusan National University Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-22
Primary Completion
2019-11-30
Completion
2020-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02976194 on ClinicalTrials.gov